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Abstract
Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative 
treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible 
morbidity and mortality. Crucial questions in clinical decision making include the definition of 
optimal timing of the procedure and the benefit of cytoreduction before transplant in high risk 
patients. We carried out a decision analysis on 1728 MDS who received supportive care, 
transplantation or hypomethylating agents (HMAs). Risk assessment was based on the revised 
International Prognostic Scoring System (IPSS-R). We used a continuous-time multistate Markov 
model to describe the natural history of disease and evaluate the effect of different treatment 
policies on survival. Life expectancy increased when transplantation was delayed from the initial 
stages to intermediate IPSS-R risk (gain of life expectancy 5.3, 4.7 and 2.8 years for patients aged 
≤55, 60 and 65 years, respectively), and then decreased for higher risks. Modelling decision 
analysis on IPSS-R vs. original IPSS changed transplantation policy in 29% of patients, resulting 
in a 2-year gain in life expectancy. In advanced stages, HMAs given before transplant is associated 
with a 2-year gain of life expectancy, especially in older patients. These results provide a 
preliminary evidence to maximize the effectiveness of allo-SCT in MDS.
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Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions 
with a near-normal life expectancy to forms approaching AML.1,2 A risk-adapted treatment 
strategy is mandatory, and the definition of individual risk requires the use of prognostic 
systems.3,4 In 1997 the International Prognostic Scoring System (IPSS) has been developed 
and become a benchmark for clinical trials and decision making.5 Nonetheless, a not 
negligible heterogeneity was observed in IPSS subgroups, in particular in patients classified 
in low and intermediate-1 risk categories. Recently, the International Working Group for 
Prognosis in MDS (IWG-PM) revised the IPSS.6 On the basis of a large data set that 
allowed the prognostic value of even less frequent karyotypic abnormalities to be estimated, 
5 cytogenetic risk groups were determined representing the basis for the revised IPSS (IPSS-
R), together with refined categories for bone marrow blasts and peripheral blood cytopenias. 
IPSS-R improved the capability to capture prognostic information in untreated MDS (where 
it identifies five risk groups compared to the four major prognostic categories that are 
present in the IPSS) as well as in patients receiving disease modifying treatments.7,8
The only curative treatment for MDS patients is allogeneic stem cell transplantation (allo-
SCT) which is considered as a conventional therapeutic option until the age of 65-70 in 
eligible patients.9–12 Its efficacy, however, is considerably limited by morbidity and 
mortality, resulting in a long-term survival rate of about 30%.12,13
Several issues must be taken into account when considering allo-SCT and evaluating its 
benefits in the individual patient with MDS. A crucial question is timing of transplant 
procedure. A number of studies have shown that advanced disease stage at transplantation is 
associated with inferior overall survival.10–13 However, patients at early stages may 
experience long periods with stable disease after diagnosis, and the risks of morbidity and 
mortality related to allo-SCT would be unacceptably high for many of them.14 A previous 
decision analysis by the International Bone Marrow Transplant Registry (IBMTR) 
concluded that for patients with low and intermediate-1 IPSS-risk delayed transplantation 
offered optimal survival benefit.15 This study has substantially influenced clinical practice 
despite a number of intrinsic limitations. In particular, the IBMTR analysis considered 
patients at the time of MDS diagnosis, ignoring changes in their disease status that 
frequently occur before transplantation or leukemic evolution and significantly affect clinical 
outcome.
In patients with advanced disease, in which immediate transplantation is clearly associated 
with survival advantage, a crucial issue is whether performing cytoreductive therapy before 
allo-SCT. The achievement of complete remission improves post-transplantation outcome in 
high risk patients. 11,16,17 However, significant concerns about chemotherapy (especially 
AML-like chemotherapy) include low response rate and risk of long-lasting 
myelosuppression and organ toxicities, possibly affecting the eligibility to the transplant 
procedure.18
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Hypomethylating agents (HMAs) have been found to be active in MDS, with a good toxicity 
profile compared with induction chemotherapy, and may therefore be of interest if used 
before transplantation.19–21
In this study we carried out an ad hoc decision analysis to address these issues. Decision 
analysis is a technique which allows to to measure the consequences of many strategies 
(treatment policies), under different conditions (disease status) and is used to address clinical 
relevant questions in the absence of evidence form randomized studies. Markov models are 
frequently used in decision analysis to stratify the natural history of a disease in different 
states.22–24
We analyzed 1728 MDS patients. We used a continuous time multistate Markov model to 
describe the natural history of disease according to IPSS-R risk categories. We specifically 
aimed: i) to evaluate the effect of allo-SCT on survival under different transplantation 
policies in patients with early disease stage, and ii) to evaluate the possible gain of life 
expectancy by using HMAs before transplantation in patients with advanced disease
Subjects and Methods
Patient population
These investigations were approved by the Ethics Committee of the Fondazione Istituto di 
Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy and 
GITMO. All procedures were carried out in accordance with the ethical standards of the 
Declaration of Helsinki.
We analyzed different cohorts of MDS patients. The first cohort included 961 patients 
diagnosed with MDS according to WHO criteria25 at the Fondazione IRCCS Policlinico 
San Matteo, Pavia, Italy, between 1992 and 2010. The second cohort included 489 
undergoing allo-SCT for primary MDS or AML evolved from MDS between 1997 and 
2010, and reported to the GITMO registry. Secondary AML was included in this analysis 
since this condition is very close to RAEB-2, and not infrequently difficult to be 
distinguished from this latter condition. Most of these patients with AML evolved from 
MDS had the condition previously defined as refractory anemia with excess of blasts in 
transformation (RAEB-t), characterized by 20–29% blasts in the bone marrow. Different 
conditioning regimens and different donor types were used. Disease-related risk was 
evaluated by using IPSS-R. In the Pavia cohort, patients were essentially treated with best 
supportive care and regularly followed-up, and this allowed clinical data and disease staging 
to be monitored longitudinally. In the GITMO cohort, all clinical variables were analyzed at 
the time of transplantation in patients undergoing allo-SCT upfront, and at the time of 
remission-induction chemotherapy in those receiving treatment before allo-SCT. The effect 
of treatment with hypomethylating agents administered before transplantation was obtained 
from an analysis of the results of two studies including 278 patients treated with azacitidine. 
19,26 (Table 1)
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We adopted a continuous-time, multistate Markov approach to model the course of the 
disease in MDS patients.27 We estimated expected survival under different treatment 
policies where the IPSS-R prognostic score is used to determine timing of allo-SCT. In high 
risk patients each policy was in addition be modified by treatment with HMAs performed 
before transplant.
A multistate model describes how an individual moves between a series of states in time. 
Markov models are multistate models based on Markov processes, that is, stochastic 
processes with the property that the probability of moving to a particular state in the future 
only depends on this state and not on past states. Further information on Markov models is 
reported in Supplemental File 1. A continuous-time Markov model was used to estimate the 
risk of progression from each disease state to the next one. We fitted a model based on IPSS-
R risk. (Figure 1). Each risk category was represented by a state in the model, and death was 
considered as absorbing state, that is, a state in which transitions to other states are not 
allowed. Transitions were allowed from any IPSS-R to the next one, to AML and to death. 
Transition intensity, that is, the instantaneous risk of moving to another state, was then 
estimated for each possible transition between states.
Allo-SCT and treatment with HMAs were modeled as a categorical time-dependent 
covariates, to allow for excess of mortality due to transplant-related causes. The effect of 
allo-SCT (alone or with HMAs) on mortality in each disease state was estimated as a hazard 
ratio (HR) with respect to the “no allo-SCT” category. Since allo-SCT does not represent an 
option for very low IPSS-R risk patients, the HRs for transplantation in this state were not 
modeled. A more detailed technical description of the models is reported in supplemental 
File 1.
The expected survival, that is, the expected time spent by a patient in the model before 
reaching the absorbing state (death), under different transplant policies was calculated 
algebraically for the fitted Markov model. These calculations were validated by 
microsimulation, and a confidence interval was obtained by bootstrap resampling.
The effect of treatment with hypomethylating agents is obtained from an analysis of the 
results of two studies.19,26 To estimate expected survival in the periods when HMAs are 
given, the equivalent HMAs-free survival times (estimated from the cohort data) are 
multiplied by the ratio of expected survival time.
Life expectancy was also estimated accounting for quality of life (QoL), based on quality-
adjusted life years (QALY).28,29 We made QoL adjustments by incorporating utilities into 
estimation of life expectancy. Utilities are numerical representations of the perceived value 
of a given health state and are expressed as values between 0 (a health state equivalent to 
being dead) and 1 (perfect health). To account for worsening of QoL with disease 
progression or transplant-related complications, we defined plausible utilities using 
previously published data. Analyses with and without adjustment for QoL were performed 
independently.
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The Markov models were implemented with the msm package for R (R Development Core 
Team 2009) 30 freely available from http://CRAN.R-project.org/package5msm.
Results
Outcome of MDS patients classified according to IPSS-R
In the Pavia cohort, IPSS-R significantly stratified the probability of survival of MDS 
patients (P<.001) (Figure 2A). The cumulative incidences of disease progression and of 
death for each IPSS-R category are reported in Supplemental Table 1.
Compared to the Pavia cohort, the GITMO cohort was younger (P<.001), and had a higher 
proportion of cases with more advanced IPSS-R (P<.001). IPSS-R significantly stratified 
post-transplantation survival (P<.001) (Figure 2B). In an exploratory multivariate survival 
analysis, type of donor (HLA-sibling or MUD) and of conditioning (standard or reduced-
intensity) did not significantly affect post-transplant survival. (Supplemental Table 2) 
Therefore, all the above types of donor and conditioning regimen were included in the 
subsequent decision analysis. The HMAs cohort included a higher proportion of cases with 
more advanced disease compared to the Pavia cohort (P<.001), while no significant 
difference was found on demographic factors; compared to the GITMO cohort, the HMAs 
cohort was older (P<.001).
IPSS-R based transplantation policies
We fitted a model of the clinical course of MDS in which patients were stratified according 
to IPSS-R. As a first step we analysed the goodness of fit of the IPSS-R-based Markov 
model as compared to the observed survival. No major lack of fit was highlighted in either 
model (not shown).
We then focused on the effect of allo-SCT on survival. In lower IPSS-R risk categories, the 
HRs after transplantation were very high, due to the risk of NRM, as compared to a 
relatively low mortality in non transplanted patients. This was not observed in higher IPSS-R 
risk categories, where mortality in non transplanted subjects is much higher. The HRs 
associated with transplantation are reported in Supplemental Table 1. In order to assess the 
optimal transplantation timing, the expected survival since diagnosis according to the IPSS-
R model was calculated for different transplant policies.
We analysed two different treatment policies, as follows.
Policy A: perform transplant in state 2 (low IPSS-R) at t years since entering the state (t 
ranging from 0 to 5), or immediately in case of disease progression before the planned delay 
time t.
Policy B: do not transplant while in state 2; perform transplant in state 3 (intermediate- 
IPSS-R) at t years since entering the state (t ranging from 0 to 5), or immediately in case of 
disease progression before the planned delay time t.
Each policy was evaluated for a set of different ages at diagnosis (between 30 and 70, with 
5-year intervals). Under all policies, the patient lost eligibility to transplantation at 70 years 
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of age. According to the model, a patient with a low IPSS-R risk is expected to spend 3.66 
years in this low risk group, 2.36 years in the intermediate risk group, and 1.58 years in the 
high risk group. The cumulative incidence of progression from low to a higher IPSS-R risk 
was 27% at 3 years, and that form intermediate to a higher risk was 39%.
Life expectancy (evaluated since time of diagnosis) under different treatment policies is 
reported in Table 2. Overall, expected survival times from diagnosis were higher under 
policy B vs policy A. Gain in expected survival since diagnosis according to the IPSS-R 
model under transplant policy B with respect to a non-transplantation policy were 5.3 years 
for a patient aged ≤55 years, 4.7 years for a patient aged 60 years and of 2.8 years for a 
patient aged 65 years. (Figure 3)
Expected survival times were up to three years greater under policy B with respect to policy 
A for younger patients. When the waiting time before transplantation was progressively 
increased from 0 to 5 years, there was an increase in expected survival under policy A (in 
younger patients this increases by about two further years if transplant is delayed until 5 
years in low IPSS-R risk state). Conversely, under policy B, delaying transplant further 
reduces expected survival, by up to about three years with a delay of 5 years after entering 
intermediate risk state or further progression to high risk state. (Figure 3)
Delaying transplantation after progression to high IPSS-R resulted in lower values for life 
expectancy compared to those estimated according to policy B, irrespective of the delay time 
t. (not shown)
According to these findings, delayed transplantation strategy is advisable for patients with 
early disease, i.e. very low and low IPSS-R risk, whereas no further delay is advised for 
patients belonging to intermediate or higher risk categories.
We also calculated the life expectancy based on quality-adjusted life years (QALY). With 
respect to the natural course of the disease, we assigned QALY51 to the very low IPSS-R 
risk; QALY50.95 to low and intermediate IPSS-R; and QALY50.90 to high and very high 
IPSS-R. Evolution to AML was assigned QALY50.85. In patients receiving transplantation, 
the onset of chronic graft versus host disease, observed in about 30% of cases, lowers the 
QoL to 0.85: therefore, we set up an average QALY value of 0.9 for post-allogeneic HSCT 
survival. Adjustment for QoL did not affect the preferred treatment strategy for any of the 
IPSS-R risk groups (not shown).
In order to evaluate the extent to which making a decision based on IPSS rather than IPSS-R 
may lead to a different transplantation strategy in early disease stage, we cross-tabulated the 
distribution of patients in the Pavia cohort according to their IPSS and IPSS-R scores. 
Among patients who at any point during follow-up were classified as low-intermediate1 risk 
IPSS and therefore candidate to a delayed transplantation according to an IPSS-based 
strategy,15 29% had an intermediate or higher IPSS-R score at the same time, and as a 
consequence would benefit from an immediate transplantation according to a IPSS-R based 
strategy. Overall, there was a 2-year gain in life expectancy using the IPSSR-based policy, 
and this gain was maximized in younger patients (gain of life expectancy under IPSSR-
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based policy vs. IPSS-based policy was 2.62, 1.5 and 0.6 years for patients aged ≤55, 60 and 
65 years, respectively)
Effect of hypomethylating agents before transplantation
We then aimed to include the effect of HMAs given as pre-transplant treatment to reduce 
disease burden in advanced MDS stages.
The effect of treatment with HMAs was obtained from an analysis of the results of two 
studies, including 278 patients treated with azacitidine. The first study19 presented a hazard 
ratio (for overall survival, between HMAs and conventional care) of HR = 0.58 (0.43, 0.77). 
This is converted to a ratio of expected survival times, 1/HR = 1.72 (1.30, 2.33), which 
assumes an exponential survival distribution 1. The second study 26 presented median 
overall survival times of 20 (16,26) months in HMAs and 14 (12, 14) in conventional care. 
The ratio of medians is assumed to be the same as the ratio of means, and a CI for the ratio 
1.43 (1.10, 1.86) is obtained by simulation. The pooled estimate, using fixed-effects meta-
analysis on the log scale, is 1.55 (1.27, 1.89). To estimate expected survival in the periods 
when HMAs are given, the equivalent HMA-free survival times (estimated from the cohort 
data) are multiplied by the ratio of expected survival times.
The following policies are evaluated.
C. Delay transplant until progression to state 3 (intermediate IPSS-R), and then an optional 
further delay between 0 and 5 years spent in state 3, versus the same but with HMAs 
treatment beginning on entry to state 3 and ending if transplant is given.
D. Delay transplant until progression to state 4 (high IPSS-R), and then an optional further 
delay between 0 and 5 years spent in state 4, versus the same but with HMAs treatment 
beginning on entry to state and ending if transplant is given.
HMA treatment is associated with up to about 2 years longer survival with respect to allo-
SCT alone. Intervention in state 3 (IPSS-R intermediate risk) is associated with longer 
survival than intervention in state 4-5 (IPSS-R high and very high risk). (Figure 4)
Gain in expected survival since diagnosis under policy C (intervention in state 3 – 
intermediate IPSS-R) performing HMAs before transplantation vs. allo-SCT alone were 1.3 
years for a patient aged ≤55 years, 1.6 years for a patient aged 60 years and of 2.4 years for a 
patient aged 65 years (Figure 4).
Discussion
Patients with MDS may be diagnosed at any stage of the disease, and their life expectancy 
may vary from several years to few months according to the disease-related risk, which can 
be assessed using prognostic scores.1,4–6,14,27
Although transplantation early after diagnosis of MDS is associated with the most 
favourable post-transplantation outcome, it remains unclear whether early transplantation 
leads to maximal life expectancy for patients with early stage MDS that may experience a 
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long period of stable disease after diagnosis.8–11 A previous decision analysis by the 
IBMTR based on a discrete-time Markov model and concluded that life expectancy of 
patients with low or intermediate-1 IPSS risk was higher when transplantation was delayed 
but performed before the progression of AML. Conversely, for high-risk MDS 
transplantation soon after diagnosis conferred the best prognosis.15 This analysis, however, 
had some weakness mainly lying in the nature of the data. In fact, clinical features of the 
non-transplantation cohort were available only at diagnosis and at the time of leukemic 
progression or death.26 Therefore, this model did not account for disease progression to 
higher risk categories, which is typical of the natural course of the disease and may 
significantly affect clinical outcome.14 Nonetheless, a not negligible heterogeneity was 
observed in IPSS low and intermediate-1 subgroups, and the original score does not include 
relevant prognostic factors i.e., severe anemia and recently refined cytogenetic risk.6,7 
Finally, only patients receiving myeloablative conditioning who were 60 years old or 
younger were considered. In last years the use of RIC was significantly increased and 
currently allo-SCT is offered as a therapeutic option in eligible patients until the age of 
65-70.
The present study included a cohort of untreated MDS patients with longitudinal clinical 
data. On this basis, we adopted a continuous-time Markov approach to model the natural 
course of MDS.27 Data on transplanted patients from the GITMO registry were then used to 
estimate the effect of transplantation on survival. In addition we adopted IPSS-R, which was 
shown to improve the prognostic stratification of low-grade MDS and significantly stratify 
the outcome of transplantation.6–8
Using IPSS-R, the estimated life expectancy was maximized when transplantation was 
delayed until progression from the very low or low risk to the intermediate risk, and then 
decreased. Within the low and intermediate-1 IPSS risk, IPSS-R identifies a subgroup of 
patients (29%) who may benefit from early transplantation. Overall, there was a 2-year gain 
in life expectancy using the IPSSR-based policy, and this gain was maximized in younger 
patients.
The availability of HMAs, including azacitidine and decitabine, has changed the landscape 
of treatment of advanced-stage MDS. Azacitidine results in hematologic improvements in 
approximately 25-50% of cases and complete response in 10-20% with improved survival 
compared to supportive care alone in high-risk MDS and with a good toxicity profile 
compared with induction chemotherapy.19,26 Although HMAs can induce hematological 
and cytogenetic responses, these therapies do not appear to eradicate MDS clones, 19,20,26 
and recent data suggest that even in patients aged 60 to 70 years with advanced disease, 
transplantation offers overall and quality-adjusted survival benefit with respect to non-
transplant procedures (including HMAs). 32
The use of HMAs is increasing as a bridge to more definitive therapy, as a part of a 
comprehensive strategy to prevent relapse after allo-HSCT in high risk patients. Several 
studies have evaluated the role of HMAs given before transplantation, though very few were 
conducted prospectively. Overall, these investigations showed similar posttransplantation 
outcome for patients receiving HMAs vs. remission-induction chemotherapy, without 
Della Porta et al. Page 9













significant treatment-related toxicity.21,33 Moreover, in some cases an improved outcome of 
patients transplanted in complete remission compared to those with active disease at the time 
of allo-SCT was reported. 21,33.
Our decision analysis seems to suggest that HMAs given before transplantation in advanced 
MDS stages is associated with a gain of life expectancy, specially in older patients (most of 
which received RIC and therefore are at higher risk of disease relapse).
In the absence of data from prospective trials on patients with MDS who are candidates for 
allo-SCT, at present, the decision to perform a cytoreductive treatment should be made on an 
individual basis, accounting for clinical considerations with respect to each specific patient.
16–18 As the rate of complete remissions is generally higher with induction chemotherapy 
compared to HMAs, that strategy might still be the best option in selected medically fit 
patients e.g. in the context of innovative transplant protocols and the immediate availability 
of a suitable donor. On the other hand, HMAs could be considered mainly for older patients 
(including those with extra-hematological comorbidity) which are at risk of losing eligibility 
for a transplantation procedure as a result of death or treatment-related toxicity and as a 
bridging strategy to allo-SCT in those where no donor has yet been identified.4,18,21
There are potential limitations in our analysis. First, our model did not into account for some 
patient-related factors which may affect post-transplantation outcome, such as comorbidity. 
In addition, methodological limitations of Markov models are to be considered. One point is 
the potential bias in the effect of transplantation from failing to account for early treatment-
related mortality. By modelling a time-dependent effect of allo-SCT, our multi-state model 
can separate early treatment-related mortality from later survival benefits from treatment. 
However, these effects are estimated from observational data, which assume that selection of 
patients for transplant is related only to predictors of survival that are modelled, in our case, 
the IPSS-R risk score.34
In summary, the findings of our study indicate that a delayed transplantation strategy is 
advisable for patients with early disease, that is, those with very low or low IPSS-R risk. 
Allogeneic HSCT should instead be immediately offered to eligible patients belonging to 
intermediate risk category, since this strategy offers the best survival benefit. In advanced 
disease stages, preliminary evidence suggest that HMAs administered before transplant, may 
have a positive impact on life expectancy. In the absence of prospective randomized data, 
these results provide clinicians with a base of evidence to maximize the effectiveness of allo-
SCT in MDS patients.
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Markov continuous-time Multi-State Models of the MDS natural history. IPSS-R risk scores 
were adopted as time-dependent indicators of the natural course of MDS. Allo-SCT was 
modelled as a time-dependent covariate, and its effect on survival was estimated as a hazard 
ratio with respect to the “no allo-SCT” category. Solid arrows represent transitions according 
to the natural course of the disease, whereas the effect of allo-SCT on mortality (i.e. 
transition to death) in each state is represented by dot arrows.
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Overall survival of MDS patients. A: overall survival in the Pavia cohort classified by time-
dependent IPSS-R; B: overall survival in the GITMO cohort classified into IPSS-R groups 
evaluated at the time of allo-SCT.
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Gain in expected survival under different transplant policies with respect to a 
nontransplantation policy. We assumed that the MDS patient was classified as very low 
IPSS-R risk at the time of diagnosis. Each policy was then evaluated for a set of different 
ages at diagnosis (as shown in the box) and for different waiting times t (between 0 and 5 
years since entering any disease state).
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Expected additional survival (compared to no-intervention), by transplant policy, age and 
treatment with HMA.
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Table 1
Clinical characteristics of patients classified according to WHO criteria. A) patients of the Pavia cohort, that 
included subjects who mainly received supportive care and were regularly followed-up. B-C) patients of the 
GITMO transplantation cohort classified according to WHO criteria (B, clinical characteristics and C, 




Number of patients 961
Median age (range) 66 (19-81)
Sex (male/female) 557(58%)/404(42%)
WHO classification:*
            RCUD 173 (18%)
            RARS 96 (10%)
            MDS del (5q) 48 (5%)
            RCMD 356 (37%)
            RAEB-1 153 (16%)
            RAEB-2 134 (14%)
Hb (g/dl) 9.3 (6.4-13.5)
Absolute Neutrophil Count (x10^9 L) 1.430 (0.10-3.290)
PLT (x10^9 L) 105 (5-732)
Cytogenetics ** 874/961 (91%)
          Very low risk 26 (3%)
          Low risk 603 (69%)
          Intermediate risk 149 (17%)
          Poor risk 61 (7%)
          Very poor risk 35 (4%)
Transfusion-dependency *** 317 (33%)
IPSS-R risk 874/961 (91%)
            Very-low 157 (18%)
            Low 244 (28%)
            Intermediate 184 (21%)
            High 219 (25%)
            Very high 70 (8%)
Treatment
         Supportive care 711 (74%)
         Erythropoietin 173 (18%)
         Lenalidomide 11 (1%)
         Low-dose chemotherapy 19 (2%)
         Hypomethylating agents 106 (11%)
         AML-like chemotherapy 38 (4%)
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A) Pavia cohort
Characteristics at diagnosis
         Allo-SCT 67 (7%)
B) GITMO Transplantation cohort
Characteristics at transplantation* MDS AML-MDS**
Number of patients 344 145
Median age 48 (19-68) 47 (21-70)
Sex (Male/Female) 179 (52%)/165(48%) 74(51%)/71(49%)
WHO classification:
       RCUD/RARS/MDS del(5q) 31 (9%) -
       RCMD 76 (22%)
       RAEB-1 86 (25%)
       RAEB-2 151 (44%)
Hb (g/dl) 9.2 (6.9-12.8) 8.7 (6.4-11)
Absolute Neutrophil Count (x10^9 L) 1.12 (0.01-8.3) 1.18 (0.2-2.4)
PLT (x10^9 L) 53 (3-491) 48 (7-231)
Cytogenetics:*** 320/344(93%) 117/145 (81%)
       Very Good 3 (1%) -
       Good 163 (51%) 51 (44%)
       Intermediate 84 (26%) 32 (27%)
       Poor 38 (12%) 19 (16%)
       Very Poor 32 (10%) 15 (13%)
Transfusion-dependency**** 230/344 (67%) 110/145 (76%)
IPSS-R risk 320/344(93%) 117/145 (81%)
       Very-low -
       Low 38 (12%)
       Intermediate 77 (24%) 8 (7%)
       High 166 (38%) 56 (48%)
       Very high 39 (26%) 53 (45%)
c) Transplant-related features of 489 patients classified according to WHO criteria
MDS AML-MDS
Number of patients 344 145
Time from diagnosis to allo-SCT (months) 10 (1-313) 8 (1-352)
Type of donor:*
      Sibling 224 (65%) 91 (63%)
      Unrelated donor 120 (35%) 54 (37%)
Source of Hematopoietic Stem Cells:
      Peripheral blood / Cord blood 217 (63%) 81 (56%)
      Bone marrow 127 (37%) 64 (44%)
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c) Transplant-related features of 489 patients classified according to WHO criteria
MDS AML-MDS
Untreated: 251/344 (73%) 13/145 (9%)
Remission-induction treatment: ** 93/344 (27%) 129/145 (89%)
       Complete remission 47/93 (51%) 57/129 (44%)
 - AML-like chemotherapy 67/93 (72%) 120/129 (93%)
       Complete remission 38/67 (57%) 54/120 (45%)
 - HMAs 26/93 (28%) 9/129 (7%)
       Complete remission 9/26 (35%) 3/9 (33%)
Conditioning regimen***
    Standard conditioning regimen 220 (64%) 91 (63%)
    Reduced-intensity conditioning (RIC) 124 (36%) 54 (37%)
D) HMA cohort
Clinical features# Silverman et al (2002)* Fenaux et al (2009)**
Number of patients 99 179
Median age 69 (31-92) 69 (42–83)
Sex (Male/Female) 72(73%)/27(27%) 132 (74%)/47 (26%)
WHO classification:
       RCUD/RARS/MDS del(5q) 22 (22%) -
       RCMD -
       RAEB-1 32 (32%) 14 (8%)
       RAEB-2 98 (55%)
       MDS/AML 27 (27%) 55 (31%)
       Other 18 (18%) 12 (7%)
Cytogenetics:*** 170/179 (95%)
      Good 83 (49%)
      Intermediate 37 (22%)
      Poor 50 (29%)
IPSS risk 163/179 (91%)
       Low 2 (2%) -
       Intermediate-1 21 (26%) 5 (3%)
       Intermediate-2 9 (11%) 76 (47%)
       High 7 (9%) 82 (50%)
Azacitidine, cicles (n) 9 (4-15)
       Complete remission 7 (7%) 30 (17%)
       Partial remission 16 (16%) 21 (12%)
       Stable disease 37 (37%) 75 (42%)
*
RCUD: refractory cytopenia with unilineage dysplasia; RARS: refractory anemia with ringed sideroblasts; MDS del(5q): myelodysplastic 
syndrome with del(5q); RCMD: refractory cytopenia with multilineage dysplasia; RAEB: refractory anemia with excess blasts.
**
cytogeneitc risk was stratified according to IPSS-R criteria
***
transfusion dependency was defined according to WPSS criteria
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*
all clinical variables were analyzed at the time of transplantation in patients undergoing upfront allogeneic-SCT and at the time of remission-
induction chemotherapy in those receiving treatment before transplantation
**
including patients affected with AREB in transformation according to FAB classification
***
cytogeneitc risk was stratified according to IPSS-R criteria
****
transfusion dependency was defined according to WPSS criteria
*
Criteria for selection of HLA-matched unrelated donors before 2002 included low-resolution typing for HLA class I (A,B) and high-resolution 
typing for HLA-DRB1, whereas since 2002 criteria included high-resolution typing for both HLA class I (A,B,C) and class II alleles (DRB1/3/4/5, 
DQA1, DPB1).). According to GITMO policy, in the absence of an 8/8 HLA-matched donor, one allele mismatched (class I or II) donor was 
allowed. Overall 174 patients received an allo-SCT form unrelated donor (138 [79%] from matched and 36 [21%] from mismatched donor)
**
response to treatment was defined according to IWG 2006 criteria
**
Most frequent conditioning regimens included the following: total body irradiation (TBI) and cyclophosphamide (20% of cases), TBI and 
fludarabine (8%), busulphan and cyclophosphamide (30%), thiotepa and cyclophosphamide (24%), and thiotepa and fludarabine (11%). For most 
patients, graft-versus-host disease (GVHD) prophylaxis was combined cyclosporine and methotrexate. The conditioning regimens were defined as 
standard myeloablative or at reduced intensity according to internationally recognized definition (Bacigalupo et al Biol Blood Marrow Transplant. 
2009 Dec; 15(12): 1628–1633.) In patients aged ≤55 years, standard conditioning was administered in 76% of cases, while 24% of subjects 
received RIC; in patients aged > 55 years, a RIC was used in 72% of cases, while 28% of subjects received standard conditioning.
#
clinical variables were analysed before treatment with azacitidine
*
J Clin Oncol. 2002 May 15;20(10):2429-40 and
**
Lancet Oncol. 2009 Mar;10(3):223-32. Exclusion criteria for both clinical trials were: poor performance status and baseline organ dysfunction 
(total bilirubin > 1.5 ULN, AST/ALT > 2 ULN, Serum creatinine > 1.5 ULN).
***
cytogeneitc risk was stratified according to IPSS criteria
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